

14 December 2020

N4 Pharma plc

("N4 Pharma" or the "Company")

Holding(s) in Company

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has been notified that Mr. David Farrier holds a total of 12,540,385 Ordinary Shares, representing 6.92% of the total issued share capital of the Company as enlarged by the placing announced on 9 December 2020.

Enquiries:

N4 Pharma plc

Nigel Theobald, CEO
Luke Cairns, Executive Director

Via IFC Advisory

SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker

Matthew Johnson/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Tel: +44(0)20 3470 0470

Turner Pope Investments (TPI) Limited

Joint Broker

Andy Thacker

Tel: +44(0)20 3657 0050

IFC Advisory Ltd

Financial PR

Graham Herring
Zach Cohen

Tel: +44(0)20 3934 6630

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

HOLFLFVLFDLLLII